More than a decade after Japanese scientists implanted the first bioengineered blood vessel into a child with a congenital heart defect, the experimental treatment has finally made its way into clinical testing in the United States.
In response to cellular stress, proteins become ensnared in chemical traffic jams, creating a kind of widespread sluggishness scientists call “proteolethargy.”
USEFUL LINKS
CONTACT
elie@eliedolgin.com
Contact Us
Thank you for contacting us. We will get back to you as soon as possible.
Oops, there was an error sending your message. Please try again later.